Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor

Kvammen, Øivind; Myklebust, Tor Åge; Solberg, Arne; Møller, Bjørn; Klepp, Olbjørn; Fosså, Sophie D.; Tandstad, Torgrim

doi:10.1158/1055-9965.epi-15-1153

Cited by 51 publications

(37 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Relatively higher survival rates were observed in younger patients (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44) compared with older patients (65-74, 75+), particularly for sites including the stomach, lung, pancreas, B and CNS, blood (NHL) and cervix. Cancer of the oesophagus, female breast and bladder had higher survival in middle-aged groups (45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57)(58)(59)(60)(61)(62)(63)…”

Section: Resultsmentioning

confidence: 99%

“…Germany has described the 5-and 10-year relative survivals for 24 common cancer types in the 1990-1992 cohort, and the 2000-2002 period (42), and by further follow-up, site-specific survival for tumour types such as pancreatic cancer was evaluated (43). (47). Almost all these papers are from developed countries or areas; such studies rarely emanate from undeveloped areas.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer survival in Qidong between 1972 and 2011: A population-based analysis

Chen

Zhu

Zhang

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Population-based cancer survival is an improved index for evaluating the overall efficiency of cancer health services in a given region. The current study analysed the observed survival and relative survival of leading cancer sites from a population-based cancer registry between 1972 and 2011 in Qidong, China. A total of 92,780 incident cases with cancer were registered and followed-up for survival status. The main sites of the cancer types, based on the rank order of incidence, were the liver, stomach, lung, colon and rectum, oesophagus, breast, pancreas, leukaemia, brain and central nervous system (B and CNS), bladder, blood [non-Hodgkin's lymphoma (NHL)] and cervix. For all malignancies combined, the 5-year observed survival was 13.18% and the relative survival was 15.80%. Females had higher observed survival and relative survival (19.32 and 22.71%, respectively) compared with males (9.63 and 11.68%, respectively). The cancer sites with the highest five-year relative survival rates were the female breast, bladder, cervix and colon and rectum; followed by NHL, stomach, B and CNS cancer and leukaemia. The poorest survival rates were cancers of oesophagus, lung, pancreas and liver. Higher survival rates were observed in younger patients compared with older patients. Cancers of the oesophagus, female breast and bladder were associated with higher survival in middle-aged groups. Improved survival rates in the most recent two 5-year calendar periods were identified for stomach, lung, colon and rectum, oesophagus, female breast and bladder cancer, as well as leukaemia and NHL. The observations of the current study provide the opportunity for evaluation of the survival outcomes of frequent cancer sites that reflects the changes and improvement in a rural area in China.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Cancer survival in Qidong between 1972 and 2011: A population-based analysis

Chen

Zhu

Zhang

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…For example, patients with TGCTs treated with chemotherapy have a 1.5–1.9‐fold higher chance of cardiovascular disease and a 2.1‐fold higher chance of a secondary malignancy . Because of these late effects, the relative survival of patients with localized disease keeps declining even beyond 30 years of follow‐up .…”

Section: Discussionmentioning

confidence: 99%

Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease

et al. 2019

View full text Add to dashboard Cite

ObjectivesTo report the long‐term results of the sentinel node (SN) approach in patients with clinical stage I testicular tumours in our facility.Patients and MethodsWe conducted an analysis of 27 consecutive patients suspected of clinical stage I testicular germ cell tumour (TGCT) and treated with an SN procedure at our tertiary referral centre. SNs were identified using lymphoscintigraphy with or without single‐photo‐emission computed tomography with CT (SPECT/CT). Patients underwent laparoscopic retroperitoneal SN excision with inguinal orchiectomy. Patients with a tumour‐positive SN underwent adjuvant treatment. Follow‐up was conducted according to then‐current guidelines.ResultsIn two patients, no SNs were visualized on scintigraphy. In the remaining 25 patients, a median (range) of 3 (1–4) SNs per patient were removed. Two patients showed no malignancy on histopathological examination of the testis. Of the 23 patients diagnosed with TGCT (16 seminomas, seven non‐seminomas), three (13.0%) had occult metastatic disease. All 23 patients were without evidence of disease at a median (range) follow‐up of 63.9 (29.0–143.4) months.ConclusionThe SN procedure allows early identification of patients with occult metastatic disease in clinical stage I TGCT, enabling early treatment.

show abstract

“…In men with testicular germ cell cancer (TGC) the cure rate exceeds 95% (Verdecchia et al, 2007). However, long term follow-up of TGC survivors (TCS) has revealed increased morbidity and shorter life expectancy (Kvammen et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality

et al. 2017

View full text Add to dashboard Cite

The cure rate of testicular cancer exceeds 95%, but testicular cancer survivors (TCS) are at increased risk of hypogonadism (HG). It has been suggested that TCS have reduced bone mineral density (BMD), but it is unclear whether this is related to HG or a direct effect of cancer therapy. The aim of this study was to evaluate whether TCS have decreased BMD, and if BMD is related to HG and/or the cancer treatment given. We investigated 91 TCS (mean age at diagnosis: 31 years; mean 9.3 years follow-up) and equal number of age matched controls (mean age at inclusion 40.3 years and 41.2 years, respectively). Total testosterone and LH were measured. BMD was determined using dual-energy X-ray absorptiometry (DXA). Low BMD (LBD) was defined as Z-score <-1. Compared to eugonadal TCS, both TCS with untreated HG (mean difference: -0.063 g/cm ; 95% CI: -0.122; -0.004 p = 0.037) and TCS receiving androgen replacement (mean difference -0.085 g/cm ; 95% CI: -0.168; -0.003; p = 0.043) presented with statistically significantly 6-8% lower hip BMD. At the spine, L1-L4, an 8% difference reached the level of statistical significance only for those with untreated HG (mean difference: -0.097 g/cm ; 95% CI: -0.179; -0.014; p = 0.022). TCS with untreated HG had significantly increased OR for spine L1-L4 LBD (OR = 4.1; 95% CI: 1.3; 13; p = 0.020). The associations between the treatment given and BMD were statistically non-significant, both with and without adjustment for HG. In conclusion, TCS with HG are at increased risk of impaired bone health. Prevention of osteoporosis should be considered as an important part in future follow up of these men.

show abstract

Long-term Relative Survival after Diagnosis of Testicular Germ Cell Tumor

Cited by 51 publications

References 29 publications

Cancer survival in Qidong between 1972 and 2011: A population-based analysis

Cancer survival in Qidong between 1972 and 2011: A population-based analysis

Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease

Risk of low bone mineral density in testicular germ cell cancer survivors: association with hypogonadism and treatment modality

Contact Info

Product

Resources

About